| | Cancer | Skin Cancer
Aldara Cream and Skin Cancer: What You Need to Know
Regulatory Status
Aldara (imiquimod 5% cream) is FDA-approved for actinic keratosis, superficial basal cell carcinoma (sBCC), and external genital/perianal warts. It is not approved for other skin cancers (e.g., nodular BCC, squamous cell carcinoma, melanoma), though off-label use occurs.
Mechanism
Immune response modifier → activates TLR7 → cytokine release (IFN-α, TNF-α, IL-12) → local immune attack on abnormal cells.
Typical Regimen (sBCC)
Apply once daily, 5 days/week, for 6 weeks (up to 12 weeks if needed). Use under clinician supervision.
Side Effects
Local: erythema, erosion, itching, burning, scabbing, flu-like symptoms. Usually resolve after treatment.
Contraindications
- Known hypersensitivity.
- Pregnancy/breastfeeding (insufficient data).
Bottom Line
Discuss with your dermatologist whether imiquimod is appropriate for your specific lesion type and location.
Skin Cancer - Related Articles
- Non-Melanoma Skin Cancer Statistics: Incidence, Underreporting & Global Burden
- Skin Cancer Removal: Methods, Selection Criteria & What to Expect
- Light-Based Therapies for Skin Cancer: Laser & Photodynamic Treatments
- Squamous Cell Carcinoma In Situ Arising in Hypertrophic Actinic Keratosis: Case Analysis
- Eczema and Makeup: When to Avoid, What to Choose, and How to Apply Safely
- Folliculitis: Causes, Symptoms, and Treatment Options
- Scalp Melanoma Treatment & Early Detection | [Your Brand/Clinic Name]
